NAS:BGLC (Malaysia)
Â
Ordinary Shares
$
0.29
-0.0029 (-0.99%)
01:03 PM EST
Business Description
BioNexus Gene Lab Corp
NAICS : 325998
SIC : 2819
ISIN : US0906282076
Share Class Description:
BGLC: Ordinary SharesDescription
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 18.31 | |||||
| Equity-to-Asset | 0.85 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.3 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | 2.8 | |||||
| Beneish M-Score | -1.15 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -22.6 | |||||
| 3-Year Book Growth Rate | 5.4 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 49.04 | |||||
| 9-Day RSI | 47.78 | |||||
| 14-Day RSI | 45.67 | |||||
| 3-1 Month Momentum % | 0.11 | |||||
| 6-1 Month Momentum % | -33.83 | |||||
| 12-1 Month Momentum % | -54.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.97 | |||||
| Quick Ratio | 3.99 | |||||
| Cash Ratio | 2.92 | |||||
| Days Inventory | 52.34 | |||||
| Days Sales Outstanding | 39.05 | |||||
| Days Payable | 58.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.4 | |||||
| Shareholder Yield % | -1.96 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 13.48 | |||||
| Operating Margin % | -9.72 | |||||
| Net Margin % | -10.17 | |||||
| FCF Margin % | -28.63 | |||||
| ROE % | -9.89 | |||||
| ROA % | -8.39 | |||||
| ROIC % | -21.82 | |||||
| 3-Year ROIIC % | 3000.28 | |||||
| ROC (Joel Greenblatt) % | -38.99 | |||||
| ROCE % | -9.31 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.58 | |||||
| PB Ratio | 0.56 | |||||
| Price-to-Tangible-Book | 0.56 | |||||
| EV-to-EBIT | -1.5 | |||||
| EV-to-EBITDA | -1.78 | |||||
| EV-to-Revenue | 0.15 | |||||
| EV-to-FCF | -0.5 | |||||
| Price-to-GF-Value | 0.09 | |||||
| Price-to-Net-Current-Asset-Value | 0.97 | |||||
| Price-to-Net-Cash | 2.07 | |||||
| Earnings Yield (Greenblatt) % | -66.67 | |||||
| FCF Yield % | -50.36 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BGLC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioNexus Gene Lab Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 9.26 | ||
| EPS (TTM) ($) | -0.072 | ||
| Beta | 1.68 | ||
| 3-Year Sharpe Ratio | -0.87 | ||
| 3-Year Sortino Ratio | -1.22 | ||
| Volatility % | 75.72 | ||
| 14-Day RSI | 45.67 | ||
| 14-Day ATR ($) | 0.044228 | ||
| 20-Day SMA ($) | 0.29279 | ||
| 12-1 Month Momentum % | -54.45 | ||
| 52-Week Range ($) | 0.2313 - 3.39 | ||
| Shares Outstanding (Mil) | 17.97 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioNexus Gene Lab Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioNexus Gene Lab Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
BioNexus Gene Lab Corp Frequently Asked Questions
What is BioNexus Gene Lab Corp(BGLC)'s stock price today?
The current price of BGLC is $0.29. The 52 week high of BGLC is $3.39 and 52 week low is $0.23.
When is next earnings date of BioNexus Gene Lab Corp(BGLC)?
The next earnings date of BioNexus Gene Lab Corp(BGLC) is 2025-02-15 Est..
Does BioNexus Gene Lab Corp(BGLC) pay dividends? If so, how much?
BioNexus Gene Lab Corp(BGLC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers